<<Back
Chembio Determines Not to Proceed with Proposed Public Offering of Common Stock
The offering was being made pursuant to a shelf registration statement that was declared effective by the
About
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 10-20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Media contacts:
Gilmartin Group
(415) 937-5402
investor@chembio.com
Source: Chembio Diagnostics, Inc.